Dianthus Therapeutics
DNTH
93 hedge funds and large institutions have $276M invested in Dianthus Therapeutics in 2021 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 30 increasing their positions, 24 reducing their positions, and 19 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 24
0.04% more ownership
Funds ownership: 4% → 4.04% (+0.04%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
4% less funds holding
Funds holding: 97 → 93 (-4)
21% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 19
25% less capital invested
Capital invested by funds: $366M → $276M (-$90.3M)
Top Buyers
| 1 |
CC
Casdin Capital
New York
|
+$4.05M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.99M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$3.75M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$3.51M |
| 5 |
ACM
Aquilo Capital Management
San Francisco,
California
|
+$3.41M |
Top Sellers
| 1 |
TGI
TRV GP IV
Boston,
Massachusetts
|
-$9.1M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$3.59M |
| 3 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$2.42M |
| 4 |
O
OrbiMed
New York
|
-$1.03M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$1.01M |
DNTH Hedge Fund Activity: Q3 2021 in Review
93 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Dianthus Therapeutics (DNTH) for Q3 2021, worth a combined $276M — down 25% from $366M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of DNTH and 15 opened new positions — a net loss of 4 holders — while 24 trimmed existing stakes and 30 added.
The largest buyer was Casdin Capital, adding an estimated $4.05M. The largest seller was TRV GP IV, cutting an estimated $9.1M.
- 93 institutional investors held Dianthus Therapeutics (DNTH) as of Q3 2021, down from 97 in Q2 2021.
- Funds reported $276M of Dianthus Therapeutics stock for Q3 2021, down 25% quarter-over-quarter.
- 15 funds opened new Dianthus Therapeutics positions in Q3 2021 and 19 closed out, a net change of -4 holders.
- The largest Dianthus Therapeutics buyer in Q3 2021 was Casdin Capital, an estimated $4.05M added.
- The largest Dianthus Therapeutics seller in Q3 2021 was TRV GP IV, an estimated $9.1M sold.
Based on aggregated 13F filings for Q3 2021.